Other Information
+Added: Rule 10b5-1 Trading Arrangements
+Added: From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K).
+Added: During the three months ended March 31, 2025, none of the Company’s directors or officers adopted , modified or terminated a plan or other arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K).
(a) Exhibits.
6 unchanged sentences
(incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on May 21, 2024).
−Removed: Securities Purchase Agreement, dated September 28, 2024, by and between Juno Therapeutics, Inc.
−Removed: and the Registrant.
−Removed: Research Collaboration and License Agreement, dated September 28, 2024, by and between Juno Therapeutics, Inc.
−Removed: and the Registrant.
−Removed: Amendment No.
−Removed: 4 to License Agreement, dated September 27, 2024, by and between the Broad Institute, Inc.
−Removed: and the Registrant.
31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
15 unchanged sentences
Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.
−Removed: † Portions of this exhibit (indicated by asterisks) have been omitted in accordance with Item 601(b)(10) of Regulation S-K.
−Removed: + Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
−Removed: The Registrant agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.
(b) Financial Statement Schedules.
−Removed: Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Prime Medicine, Inc.
−Removed: November 12, 2024 By:
/s/ Keith Gottesdiener
−Removed: Keith Gottesdiener
+Added: May 08, 2025 Keith Gottesdiener
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 12, 2024 By:
+Added: May 08, 2025 By:
/s/ Allan Reine
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.